申请人:LIGAND PHARMACEUTICALS, INC.
公开号:US10449210B2
公开(公告)日:2019-10-22
Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver. Novel prodrug compounds of acid/alcohol derivatives such as phosphates, phosphonates, phosphonamidates, phosphoramidates, carboxylates, phenolates, and alkoxylates, their preparation and their uses are described. Some of the novel prodrug compounds described herein do not generate a vinyl keto reactive intermediate in the activation process. Another aspect includes the use of prodrugs to treat diseases that benefit from enhanced drug distribution to the liver and like tissues and cells.
本文提供的是原药化合物、其制备方法及其用途,例如通过干预肝脏中的分子通路来治疗肝脏疾病或非肝脏疾病。本文描述了酸/醇衍生物(如磷酸盐、膦酸盐、磷酰胺盐、磷酰胺盐、羧酸盐、苯酚盐和烷氧基盐)的新型原药化合物、其制备方法及其用途。本文所述的一些新型原药化合物在活化过程中不会产生乙烯酮反应中间体。另一个方面包括使用原药治疗疾病,这些疾病可受益于药物在肝脏及类似组织和细胞中的分布增强。